Published online before print April 10, 2006, doi: 10.1161/CIRCULATIONAHA.105.590083
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2006;113:1871-1878.)
© 2006 American Heart Association, Inc.
Vascular Medicine |
Heparins Increase Endothelial Nitric Oxide Bioavailability by Liberating Vessel-Immobilized Myeloperoxidase
From the Departments of Cardiology (S.B., V.R., M.R., W.D.I., T.K.R., K. Sydow, D.L., K. Szöcs, A.K., T.R., H.K., T.M., T.H.) and Cardiovascular Surgery (S.S., T.D., H.C.R.), Heart Center, and the Department of Clinical Chemistry (M.H.), University Hospital Hamburg-Eppendorf, Hamburg, Germany; and the Departments of Internal Medicine and Human Physiology (J.P.E., L.K., L.B.), University of California, Davis.
Correspondence to Stephan Baldus, MD, University Hospital Hamburg-Eppendorf, Heart Center, Department of Cardiology, Martinistrasse 52, 20246 Hamburg, Germany. E-mail baldus{at}uke.uni-hamburg.de
Received September 20, 2005; revision received January 16, 2006; accepted February 10, 2006.
Background— Neutrophils and monocytes are centrally linked to vascular inflammatory disease, and leukocyte-derived myeloperoxidase (MPO) has emerged as an important mechanistic participant in impaired vasomotor function. MPO binds to and transcytoses endothelial cells in a glycosaminoglycan-dependent manner, and MPO binding to the vessel wall is a prerequisite for MPO-dependent oxidation of endothelium-derived nitric oxide (NO) and impairment of endothelial function in animal models. In the present study, we investigated whether heparin mobilizes MPO from vascular compartments in humans and defined whether this translates into increased vascular NO bioavailability and function.
Methods and Results— Plasma MPO levels before and after heparin administration were assessed by ELISA in 109 patients undergoing coronary angiography. Whereas baseline plasma MPO levels did not differ between patients with or without angiographically detectable coronary artery disease (CAD), the increase in MPO plasma content on bolus heparin administration was higher in patients with CAD (P=0.01). Heparin treatment also improved endothelial NO bioavailability, as evidenced by flow-mediated dilation (P<0.01) and by acetylcholine-induced changes in forearm blood flow (P<0.01). The extent of heparin-induced MPO release was correlated with improvement in endothelial function (r=0.69, P<0.01). Moreover, and consistent with this tenet, ex vivo heparin treatment of extracellular matrix proteins, cultured endothelial cells, and saphenous vein graft specimens from CAD patients decreased MPO burden.
Conclusions— Mobilization of vessel-associated MPO may represent an important mechanism by which heparins exert antiinflammatory effects and increase vascular NO bioavailability. These data add to the growing body of evidence for a causal role of MPO in compromised vascular NO signaling in humans.
CLINICAL PERSPECTIVE
This article has been cited by other articles:
 |
|
 |
|
  R. E. Gandley, J. Rohland, Y. Zhou, E. Shibata, G. F. Harger, A. Rajakumar, V. E. Kagan, N. Markovic, and C. A. Hubel Increased Myeloperoxidase in the Placenta and Circulation of Women With Preeclampsia Hypertension, August 1, 2008; 52(2): 387 - 393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Heumuller, S. Wind, E. Barbosa-Sicard, H. H.H.W. Schmidt, R. Busse, K. Schroder, and R. P. Brandes Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant Hypertension, February 1, 2008; 51(2): 211 - 217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van Leeuwen, M. J.J. Gijbels, A. Duijvestijn, M. Smook, M. J. van de Gaar, P. Heeringa, M. P.J. de Winther, and J. W. C. Tervaert Accumulation of Myeloperoxidase-Positive Neutrophils in Atherosclerotic Lesions in LDLR / Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2008; 28(1): 84 - 89. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Li, A. C. Keenan, J. C. Young, M. J. Hall, Z. Pamuklar, E. M. Ohman, S. R. Steinhubl, and S. S. Smyth Effects of Unfractionated Heparin and Glycoprotein IIb/IIIa Antagonists Versus Bivalirdin on Myeloperoxidase Release From Neutrophils Arterioscler. Thromb. Vasc. Biol., August 1, 2007; 27(8): 1850 - 1856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Meuwese, E. S.G. Stroes, S. L. Hazen, J. N. van Miert, J. A. Kuivenhoven, R. G. Schaub, N. J. Wareham, R. Luben, J. J.P. Kastelein, K.-T. Khaw, et al. Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals: The EPIC-Norfolk Prospective Population Study J. Am. Coll. Cardiol., July 10, 2007; 50(2): 159 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Scalia, Y. Gong, B. Berzins, L. J. Zhao, and K. Sharma Hyperglycemia Is a Major Determinant of Albumin Permeability in Diabetic Microcirculation: The Role of {micro}-Calpain Diabetes, July 1, 2007; 56(7): 1842 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Morrow Appraisal of Myeloperoxidase for Evaluation of Patients With Suspected Acute Coronary Syndromes J. Am. Coll. Cardiol., May 22, 2007; 49(20): 2001 - 2002. [Full Text] [PDF]
|
|
|
|
|
|
T. J. Mocatta, A. P. Pilbrow, V. A. Cameron, R. Senthilmohan, C. M. Frampton, A. M. Richards, and C. C. Winterbourn Plasma Concentrations of Myeloperoxidase Predict Mortality After Myocardial Infarction J. Am. Coll. Cardiol., May 22, 2007; 49(20): 1993 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lavi, A. Prasad, E. H. Yang, V. Mathew, R. D. Simari, C. S. Rihal, L. O. Lerman, and A. Lerman Smoking Is Associated With Epicardial Coronary Endothelial Dysfunction and Elevated White Blood Cell Count in Patients With Chest Pain and Early Coronary Artery Disease Circulation, May 22, 2007; 115(20): 2621 - 2627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Borawski, B. Naumnik, and M. Mysliwiec Heparin, Myeloperoxidase, and Atherosclerosis: A New Focus on an Old Drug Clinical and Applied Thrombosis/Hemostasis, April 1, 2007; 13(2): 219 - 220. [PDF]
|
|